Gene Expression of Sirtuin-1 and Endogenous Secretory Receptor for Advanced Glycation End Products in Healthy and Slightly Overweight Subjects after Caloric Restriction and Resveratrol Administration

Sirtuin-1 (Sirt-1) and an endogenous secretory receptor for an advanced glycation end product (esRAGE) are associated with vascular protection. The purpose of this study was to examine the effects of resveratrol (RSV) and caloric restriction (CR) on gene expression of Sirt-1 and esRAGE on serum leve...

Full description

Saved in:
Bibliographic Details
Published inNutrients Vol. 10; no. 7; p. 937
Main Authors Roggerio, Alessandra, Strunz, Célia M. Cassaro, Pacanaro, Ana Paula, Leal, Dalila Pinheiro, Takada, Julio Y., Avakian, Solange D., Mansur, Antonio de Padua
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 21.07.2018
MDPI
Subjects
advanced glycation end products
Aged
blood serum
Caloric Restriction
Female
Gene expression
Gene Expression Regulation - drug effects
high density lipoprotein
Humans
low calorie diet
Male
Middle Aged
Overweight
Receptor for Advanced Glycation End Products - genetics
Receptor for Advanced Glycation End Products - metabolism
resveratrol
Sirtuin 1 - genetics
Sirtuin 1 - metabolism
Stilbenes - administration & dosage
Stilbenes - pharmacology
waist circumference
Sirt-1
caloric restriction
resveratrol
esRAGE
Online AccessGet full text
ISSN2072-6643
2072-6643
DOI10.3390/nu10070937

Cover

Abstract Sirtuin-1 (Sirt-1) and an endogenous secretory receptor for an advanced glycation end product (esRAGE) are associated with vascular protection. The purpose of this study was to examine the effects of resveratrol (RSV) and caloric restriction (CR) on gene expression of Sirt-1 and esRAGE on serum levels of Sirt1 and esRAGE in healthy and slightly overweight subjects. The study included 48 healthy subjects randomized to 30 days of RSV (500 mg/day) or CR (1000 cal/day). Waist circumference (p = 0.011), TC (p = 0.007), HDL (p = 0.031), non-HDL (p = 0.025), ApoA1 (p = 0.011), and ApoB (p = 0.037) decreased in the CR group. However, TC (p = 0.030), non-HDL (p = 0.010), ApoB (p = 0.034), and HOMA-IR (p = 0.038) increased in the RSV group. RSV and CR increased serum levels of Sirt-1, respectively, from 1.06 ± 0.71 ng/mL to 5.75 ± 2.98 ng/mL (p < 0.0001) and from 1.65 ± 1.81 ng/mL to 5.80 ± 2.23 ng/mL (p < 0.0001). esRAGE serum levels were similar in RSV (p = NS) and CR (p = NS) groups. Significant positive correlation was observed between gene expression changes of Sirt-1 and esRAGE in RSV (r = 0.86; p < 0.0001) and in CR (r = 0.71; p < 0.0001) groups, but not for the changes in serum concentrations. CR promoted increases in the gene expression of esRAGE (post/pre). Future long-term studies are needed to evaluate the impact of these outcomes on vascular health.
AbstractList Sirtuin-1 (Sirt-1) and an endogenous secretory receptor for an advanced glycation end product (esRAGE) are associated with vascular protection. The purpose of this study was to examine the effects of resveratrol (RSV) and caloric restriction (CR) on gene expression of Sirt-1 and esRAGE on serum levels of Sirt1 and esRAGE in healthy and slightly overweight subjects. The study included 48 healthy subjects randomized to 30 days of RSV (500 mg/day) or CR (1000 cal/day). Waist circumference (p = 0.011), TC (p = 0.007), HDL (p = 0.031), non-HDL (p = 0.025), ApoA1 (p = 0.011), and ApoB (p = 0.037) decreased in the CR group. However, TC (p = 0.030), non-HDL (p = 0.010), ApoB (p = 0.034), and HOMA-IR (p = 0.038) increased in the RSV group. RSV and CR increased serum levels of Sirt-1, respectively, from 1.06 ± 0.71 ng/mL to 5.75 ± 2.98 ng/mL (p < 0.0001) and from 1.65 ± 1.81 ng/mL to 5.80 ± 2.23 ng/mL (p < 0.0001). esRAGE serum levels were similar in RSV (p = NS) and CR (p = NS) groups. Significant positive correlation was observed between gene expression changes of Sirt-1 and esRAGE in RSV (r = 0.86; p < 0.0001) and in CR (r = 0.71; p < 0.0001) groups, but not for the changes in serum concentrations. CR promoted increases in the gene expression of esRAGE (post/pre). Future long-term studies are needed to evaluate the impact of these outcomes on vascular health.
Sirtuin-1 (Sirt-1) and an endogenous secretory receptor for an advanced glycation end product (esRAGE) are associated with vascular protection. The purpose of this study was to examine the effects of resveratrol (RSV) and caloric restriction (CR) on gene expression of Sirt-1 and esRAGE on serum levels of Sirt1 and esRAGE in healthy and slightly overweight subjects. The study included 48 healthy subjects randomized to 30 days of RSV (500 mg/day) or CR (1000 cal/day). Waist circumference ( = 0.011), TC ( = 0.007), HDL ( = 0.031), non-HDL ( = 0.025), ApoA1 ( = 0.011), and ApoB ( = 0.037) decreased in the CR group. However, TC ( = 0.030), non-HDL ( = 0.010), ApoB ( = 0.034), and HOMA-IR ( = 0.038) increased in the RSV group. RSV and CR increased serum levels of Sirt-1, respectively, from 1.06 ± 0.71 ng/mL to 5.75 ± 2.98 ng/mL ( < 0.0001) and from 1.65 ± 1.81 ng/mL to 5.80 ± 2.23 ng/mL ( < 0.0001). esRAGE serum levels were similar in RSV ( = NS) and CR ( = NS) groups. Significant positive correlation was observed between gene expression changes of Sirt-1 and esRAGE in RSV ( = 0.86; < 0.0001) and in CR ( = 0.71; < 0.0001) groups, but not for the changes in serum concentrations. CR promoted increases in the gene expression of esRAGE (post/pre). Future long-term studies are needed to evaluate the impact of these outcomes on vascular health.
Sirtuin-1 (Sirt-1) and an endogenous secretory receptor for an advanced glycation end product (esRAGE) are associated with vascular protection. The purpose of this study was to examine the effects of resveratrol (RSV) and caloric restriction (CR) on gene expression of Sirt-1 and esRAGE on serum levels of Sirt1 and esRAGE in healthy and slightly overweight subjects. The study included 48 healthy subjects randomized to 30 days of RSV (500 mg/day) or CR (1000 cal/day). Waist circumference ( p = 0.011), TC ( p = 0.007), HDL ( p = 0.031), non-HDL ( p = 0.025), ApoA1 ( p = 0.011), and ApoB ( p = 0.037) decreased in the CR group. However, TC ( p = 0.030), non-HDL ( p = 0.010), ApoB ( p = 0.034), and HOMA-IR ( p = 0.038) increased in the RSV group. RSV and CR increased serum levels of Sirt-1, respectively, from 1.06 ± 0.71 ng/mL to 5.75 ± 2.98 ng/mL ( p < 0.0001) and from 1.65 ± 1.81 ng/mL to 5.80 ± 2.23 ng/mL ( p < 0.0001). esRAGE serum levels were similar in RSV ( p = NS) and CR ( p = NS) groups. Significant positive correlation was observed between gene expression changes of Sirt-1 and esRAGE in RSV ( r = 0.86; p < 0.0001) and in CR ( r = 0.71; p < 0.0001) groups, but not for the changes in serum concentrations. CR promoted increases in the gene expression of esRAGE (post/pre). Future long-term studies are needed to evaluate the impact of these outcomes on vascular health.
Sirtuin-1 (Sirt-1) and an endogenous secretory receptor for an advanced glycation end product (esRAGE) are associated with vascular protection. The purpose of this study was to examine the effects of resveratrol (RSV) and caloric restriction (CR) on gene expression of Sirt-1 and esRAGE on serum levels of Sirt1 and esRAGE in healthy and slightly overweight subjects. The study included 48 healthy subjects randomized to 30 days of RSV (500 mg/day) or CR (1000 cal/day). Waist circumference (p = 0.011), TC (p = 0.007), HDL (p = 0.031), non-HDL (p = 0.025), ApoA1 (p = 0.011), and ApoB (p = 0.037) decreased in the CR group. However, TC (p = 0.030), non-HDL (p = 0.010), ApoB (p = 0.034), and HOMA-IR (p = 0.038) increased in the RSV group. RSV and CR increased serum levels of Sirt-1, respectively, from 1.06 ± 0.71 ng/mL to 5.75 ± 2.98 ng/mL (p < 0.0001) and from 1.65 ± 1.81 ng/mL to 5.80 ± 2.23 ng/mL (p < 0.0001). esRAGE serum levels were similar in RSV (p = NS) and CR (p = NS) groups. Significant positive correlation was observed between gene expression changes of Sirt-1 and esRAGE in RSV (r = 0.86; p < 0.0001) and in CR (r = 0.71; p < 0.0001) groups, but not for the changes in serum concentrations. CR promoted increases in the gene expression of esRAGE (post/pre). Future long-term studies are needed to evaluate the impact of these outcomes on vascular health.Sirtuin-1 (Sirt-1) and an endogenous secretory receptor for an advanced glycation end product (esRAGE) are associated with vascular protection. The purpose of this study was to examine the effects of resveratrol (RSV) and caloric restriction (CR) on gene expression of Sirt-1 and esRAGE on serum levels of Sirt1 and esRAGE in healthy and slightly overweight subjects. The study included 48 healthy subjects randomized to 30 days of RSV (500 mg/day) or CR (1000 cal/day). Waist circumference (p = 0.011), TC (p = 0.007), HDL (p = 0.031), non-HDL (p = 0.025), ApoA1 (p = 0.011), and ApoB (p = 0.037) decreased in the CR group. However, TC (p = 0.030), non-HDL (p = 0.010), ApoB (p = 0.034), and HOMA-IR (p = 0.038) increased in the RSV group. RSV and CR increased serum levels of Sirt-1, respectively, from 1.06 ± 0.71 ng/mL to 5.75 ± 2.98 ng/mL (p < 0.0001) and from 1.65 ± 1.81 ng/mL to 5.80 ± 2.23 ng/mL (p < 0.0001). esRAGE serum levels were similar in RSV (p = NS) and CR (p = NS) groups. Significant positive correlation was observed between gene expression changes of Sirt-1 and esRAGE in RSV (r = 0.86; p < 0.0001) and in CR (r = 0.71; p < 0.0001) groups, but not for the changes in serum concentrations. CR promoted increases in the gene expression of esRAGE (post/pre). Future long-term studies are needed to evaluate the impact of these outcomes on vascular health.
Author Avakian, Solange D.
Mansur, Antonio de Padua
Roggerio, Alessandra
Leal, Dalila Pinheiro
Takada, Julio Y.
Strunz, Célia M. Cassaro
Pacanaro, Ana Paula
AuthorAffiliation Instituto do Coração, Hospital das Clínicas—HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Av Dr Eneas de Carvalho Aguiar, 44. CEP 05403-900 São Paulo, SP, Brazil; alessandra.roggerio@incor.usp.br (A.R.); labcelia@incor.usp.br (C.M.C.S.); ana.pacanaro@incor.usp.br (A.P.P.); dalila.pinheiro.leal@hotmail.com (D.P.L.); jyt@bol.com.br (J.Y.T.); solange.avakian@incor.usp.br (S.D.A.)
AuthorAffiliation_xml – name: Instituto do Coração, Hospital das Clínicas—HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Av Dr Eneas de Carvalho Aguiar, 44. CEP 05403-900 São Paulo, SP, Brazil; alessandra.roggerio@incor.usp.br (A.R.); labcelia@incor.usp.br (C.M.C.S.); ana.pacanaro@incor.usp.br (A.P.P.); dalila.pinheiro.leal@hotmail.com (D.P.L.); jyt@bol.com.br (J.Y.T.); solange.avakian@incor.usp.br (S.D.A.)
Author_xml – sequence: 1
  givenname: Alessandra
  surname: Roggerio
  fullname: Roggerio, Alessandra
– sequence: 2
  givenname: Célia M. Cassaro
  orcidid: 0000-0002-9766-1184
  surname: Strunz
  fullname: Strunz, Célia M. Cassaro
– sequence: 3
  givenname: Ana Paula
  surname: Pacanaro
  fullname: Pacanaro, Ana Paula
– sequence: 4
  givenname: Dalila Pinheiro
  surname: Leal
  fullname: Leal, Dalila Pinheiro
– sequence: 5
  givenname: Julio Y.
  surname: Takada
  fullname: Takada, Julio Y.
– sequence: 6
  givenname: Solange D.
  surname: Avakian
  fullname: Avakian, Solange D.
– sequence: 7
  givenname: Antonio de Padua
  orcidid: 0000-0003-3051-1090
  surname: Mansur
  fullname: Mansur, Antonio de Padua
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30037068$$D View this record in MEDLINE/PubMed
BookMark eNqNUt9rFDEQXqRia-2Lf4AEfCnC6myyu9l9EcpxvQqFiqfPIZedvcuRS84ke3p_Yf8ts9dWa_HBwJAZ5vu--cG8zI6ss5hlrwt4z1gLH-xQAHBoGX-WnVDgNK_rkh098o-zsxDWMD4OvGYvsmMGwDjUzUl2O0OLZPpz6zEE7SxxPZlrHwdt84JI25Gp7dwSrRsCmaPyGJ3fky-ocJs80ie76HbSKuzIzOyVjKNKIpHP3nWDioFoS65QmrjaHwTnRi9X0ezJzQ79DxwDMh8Waxyxso_oyUQa57VKZUJM_0FypKY4cWT0zqSqG211yh8qvsqe99IEPLv_T7Nvl9Ovk6v8-mb2aXJxnauStTEvZddDCR0AgoKCU1qpRcs7SmtVQ0MrUEUFXPJ-0VVYJWt42XNJZV-WTNXsNPt4p7sdFhvsFNrUgBFbrzfS74WTWvydsXollm4nauCMl20SOL8X8O77kOYTGx0UGiMtph0LSnnRAKP0P6DAq6rktBnbevsEunaDt2kTghbQVA2vilHwzePmf3f9cA4JAHcA5V0IHnuhdDzsN82ijShAjEcn_hxdorx7QnlQ_Qf4F5vD2s4
CitedBy_id crossref_primary_10_3390_ijms24129881
crossref_primary_10_1002_biof_1531
crossref_primary_10_3390_app11062790
crossref_primary_10_3390_jcm11112985
crossref_primary_10_1016_j_dsx_2021_102224
crossref_primary_10_1038_s41392_022_01257_8
crossref_primary_10_1089_act_2020_29268_kha
crossref_primary_10_3389_fphys_2021_752117
crossref_primary_10_3390_nu12102928
crossref_primary_10_3390_ijerph192315815
crossref_primary_10_1080_10408398_2021_1962796
crossref_primary_10_3390_cells8121583
crossref_primary_10_3390_molecules26113168
crossref_primary_10_3390_nu11020386
crossref_primary_10_3390_antiox11122363
crossref_primary_10_1155_2019_8765954
crossref_primary_10_3390_ijms25020747
crossref_primary_10_2174_2665978601666200213121512
crossref_primary_10_1167_iovs_64_15_28
crossref_primary_10_1093_ckj_sfad076
crossref_primary_10_3390_cimb45050250
crossref_primary_10_3390_ijms21062124
crossref_primary_10_1186_s40001_022_00746_4
Cites_doi 10.1016/j.mad.2013.05.006
10.1038/nature16932
10.1186/ar1749
10.1161/01.ATV.0000160342.20342.00
10.1158/0008-5472.CAN-10-0595
10.1096/fj.201700031R
10.1016/j.exger.2010.03.014
10.1042/bj20021371
10.1016/j.bbagen.2013.06.014
10.1073/pnas.242407999
10.1016/j.atherosclerosis.2014.03.025
10.1155/2016/6248264
10.1146/annurev.pathol.4.110807.092250
10.1016/j.ijcard.2016.10.058
10.1007/s11695-015-1859-4
10.1126/science.1117728
10.5812/ijem.23542
10.1038/nature01960
10.1002/wrna.100
10.1111/nyas.12212
10.1126/science.1101731
10.1016/j.jada.2010.03.018
10.1902/jop.2010.100019
10.1371/journal.pone.0028926
10.1016/j.exger.2013.04.005
10.1189/jlb.1012519
10.1194/jlr.M038968
10.1016/j.cell.2006.11.013
10.1210/jc.2017-00954
10.1210/jc.2015-4069
10.1161/01.RES.84.5.489
10.1016/j.atherosclerosis.2007.07.025
10.2337/db09-1187
10.2337/db12-1528
10.1038/srep08931
10.1007/s00109-005-0688-7
10.1111/jnc.13069
10.1016/j.yjmcc.2007.08.008
ContentType Journal Article
Copyright 2018. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2018 by the authors. 2018
Copyright_xml – notice: 2018. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2018 by the authors. 2018
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TS
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
7S9
L.6
5PM
DOI 10.3390/nu10070937
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Physical Education Index
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
ProQuest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
Physical Education Index
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList AGRICOLA
MEDLINE
Publicly Available Content Database

CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 2072-6643
ExternalDocumentID PMC6073749
30037068
10_3390_nu10070937
Genre Randomized Controlled Trial
Journal Article
GroupedDBID ---
53G
5VS
7X7
88E
8FE
8FH
8FI
8FJ
A8Z
AADQD
AAFWJ
AAHBH
AAWTL
AAYXX
ABUWG
ACIWK
ACPRK
ADRAZ
AENEX
AFKRA
AFRAH
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
APEBS
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
DIK
E3Z
EBD
ECGQY
EIHBH
ESTFP
EYRJQ
F5P
FYUFA
GX1
HMCUK
HYE
IPNFZ
KQ8
LK8
M1P
M48
MODMG
M~E
OK1
P2P
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RIG
RNS
RPM
TR2
UKHRP
3V.
ATCPS
BBNVY
BHPHI
CGR
CUY
CVF
ECM
EIF
GROUPED_DOAJ
HCIFZ
M0K
M7P
NPM
7TS
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
7S9
L.6
5PM
ID FETCH-LOGICAL-c439t-4adf040d00e0c017225cb97d226c608250c1507a7fbd5e5d5e874f7a2af443c63
IEDL.DBID 7X7
ISSN 2072-6643
IngestDate Thu Aug 21 13:43:02 EDT 2025
Thu Jul 10 18:48:28 EDT 2025
Thu Jul 10 17:28:02 EDT 2025
Fri Jul 25 20:19:40 EDT 2025
Wed Feb 19 02:43:04 EST 2025
Thu Apr 24 23:00:08 EDT 2025
Tue Jul 01 02:30:22 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords Sirt-1
caloric restriction
resveratrol
esRAGE
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c439t-4adf040d00e0c017225cb97d226c608250c1507a7fbd5e5d5e874f7a2af443c63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0003-3051-1090
0000-0002-9766-1184
OpenAccessLink https://www.proquest.com/docview/2108587519?pq-origsite=%requestingapplication%
PMID 30037068
PQID 2108587519
PQPubID 2032353
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6073749
proquest_miscellaneous_2271803229
proquest_miscellaneous_2075547286
proquest_journals_2108587519
pubmed_primary_30037068
crossref_citationtrail_10_3390_nu10070937
crossref_primary_10_3390_nu10070937
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-07-21
PublicationDateYYYYMMDD 2018-07-21
PublicationDate_xml – month: 07
  year: 2018
  text: 2018-07-21
  day: 21
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Nutrients
PublicationTitleAlternate Nutrients
PublicationYear 2018
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Howitz (ref_20) 2003; 425
Koyama (ref_41) 2014; 234
Mulrennan (ref_18) 2015; 10
Basta (ref_23) 2008; 196
Busch (ref_32) 2012; 3
Pullerits (ref_39) 2005; 7
ref_36
Ristow (ref_2) 2010; 45
Holly (ref_34) 2013; 134
Yonekura (ref_26) 2003; 15
Kierdof (ref_27) 2013; 94
Urbano (ref_28) 2016; 101
Schmidt (ref_13) 1999; 84
Lagouge (ref_5) 2006; 127
Liu (ref_33) 2015; 133
Kanarek (ref_38) 2013; 54
Moridi (ref_31) 2015; 13
Evankovich (ref_37) 2017; 31
Mansur (ref_7) 2017; 15
Ota (ref_9) 2007; 43
Aris (ref_30) 2010; 81
Park (ref_22) 2001; 16
Vlassara (ref_11) 2002; 99
Uribarri (ref_12) 2010; 110
Brett (ref_10) 1993; 143
Ceolotto (ref_14) 2010; 59
Nemoto (ref_4) 2004; 306
Hudson (ref_15) 2008; 22
Selvin (ref_17) 2013; 62
Kalea (ref_24) 2010; 70
Lan (ref_19) 2013; 48
Bierhaus (ref_25) 2005; 83
Baker (ref_35) 2016; 530
Nisoli (ref_3) 2005; 310
Haddad (ref_40) 2016; 2016
Haigis (ref_1) 2010; 5
Kitada (ref_8) 2013; 1830
Mariani (ref_6) 2016; 26
Mangiafico (ref_29) 2017; 102
Falcone (ref_16) 2005; 25
Barger (ref_21) 2013; 1290
12939617 - Nature. 2003 Sep 11;425(6954):191-6
25892997 - Int J Endocrinol Metab. 2015 Apr 20;13(2):e23542
21196183 - Front Biosci (Landmark Ed). 2011 Jan 01;16:486-97
26840489 - Nature. 2016 Feb 11;530(7589):184-9
26885882 - J Clin Endocrinol Metab. 2016 Apr;101(4):1701-9
20497781 - J Am Diet Assoc. 2010 Jun;110(6):911-16.e12
22174926 - PLoS One. 2011;6(12):e28926
25689357 - J Neurochem. 2015 Apr;133(2):187-98
18089847 - FASEB J. 2008 May;22(5):1572-80
17826783 - Atherosclerosis. 2008 Jan;196(1):9-21
27829696 - Dis Markers. 2016;2016:6248264
16224023 - Science. 2005 Oct 14;310(5746):314-7
24727234 - Atherosclerosis. 2014 Jun;234(2):329-34
28029409 - Int J Cardiol. 2017 Jan 15;227:788-794
20068143 - Diabetes. 2010 Apr;59(4):1006-15
23855474 - Ann N Y Acad Sci. 2013 Jul;1290:122-9
23543766 - J Leukoc Biol. 2013 Jul;94(1):55-68
16133426 - J Mol Med (Berl). 2005 Nov;83(11):876-86
12495433 - Biochem J. 2003 Mar 15;370(Pt 3):1097-109
20570900 - Cancer Res. 2010 Jul 1;70(13):5628-38
17916362 - J Mol Cell Cardiol. 2007 Nov;43(5):571-9
28515150 - FASEB J. 2017 Sep;31(9):3894-3903
20350594 - Exp Gerontol. 2010 Jun;45(6):410-8
8256857 - Am J Pathol. 1993 Dec;143(6):1699-712
23396398 - Diabetes. 2013 Jun;62(6):2116-21
28973588 - J Clin Endocrinol Metab. 2017 Oct 1;102(10):3756-3764
15731496 - Arterioscler Thromb Vasc Biol. 2005 May;25(5):1032-7
12429856 - Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15596-601
26337692 - Obes Surg. 2016 Jun;26(6):1215-20
15604409 - Science. 2004 Dec 17;306(5704):2105-8
20078221 - Annu Rev Pathol. 2010;5:253-95
15987483 - Arthritis Res Ther. 2005;7(4):R817-24
17112576 - Cell. 2006 Dec 15;127(6):1109-22
21898828 - Wiley Interdiscip Rev RNA. 2012 Jan-Feb;3(1):1-12
10082470 - Circ Res. 1999 Mar 19;84(5):489-97
23966666 - J Lipid Res. 2013 Nov;54(11):3052-61
23747814 - Mech Ageing Dev. 2013 Sep;134(9):356-66
25754382 - Sci Rep. 2015 Mar 10;5:8931
23624181 - Exp Gerontol. 2013 Oct;48(10):1018-24
20572766 - J Periodontol. 2010 Oct;81(10):1481-7
23800577 - Biochim Biophys Acta. 2013 Oct;1830(10):4820-7
References_xml – volume: 134
  start-page: 356
  year: 2013
  ident: ref_34
  article-title: Changes in splicing factor expression are associated with advancing age in man
  publication-title: Mech. Ageing Dev.
  doi: 10.1016/j.mad.2013.05.006
– volume: 530
  start-page: 184
  year: 2016
  ident: ref_35
  article-title: Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan
  publication-title: Nature
  doi: 10.1038/nature16932
– volume: 7
  start-page: R817
  year: 2005
  ident: ref_39
  article-title: Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/ar1749
– volume: 25
  start-page: 1032
  year: 2005
  ident: ref_16
  article-title: Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in non-diabetic men
  publication-title: Arterioscler. Thromb. Vasc. Biol.
  doi: 10.1161/01.ATV.0000160342.20342.00
– volume: 70
  start-page: 5628
  year: 2010
  ident: ref_24
  article-title: Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signaling
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-10-0595
– volume: 31
  start-page: 3894
  year: 2017
  ident: ref_37
  article-title: Receptor for advanced glycation end products is targeted by FBXO10 for ubiquitination and degradation
  publication-title: FASEB J.
  doi: 10.1096/fj.201700031R
– volume: 45
  start-page: 410
  year: 2010
  ident: ref_2
  article-title: How increased oxidative stress promotes longevity and metabolic health: The concept of mitochondrial hormesis (mitohormesis)
  publication-title: Exp. Gerontol.
  doi: 10.1016/j.exger.2010.03.014
– volume: 15
  start-page: 1097
  year: 2003
  ident: ref_26
  article-title: Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury
  publication-title: Biochem. J.
  doi: 10.1042/bj20021371
– volume: 1830
  start-page: 4820
  year: 2013
  ident: ref_8
  article-title: Calorie restriction in overweight males ameliorates obesity-related metabolic alterations and cellular adaptations through anti-aging effects, possibly including AMPK and SIRT1 activation
  publication-title: Biochim. Biophys. Acta
  doi: 10.1016/j.bbagen.2013.06.014
– volume: 99
  start-page: 15596
  year: 2002
  ident: ref_11
  article-title: Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.242407999
– volume: 234
  start-page: 329
  year: 2014
  ident: ref_41
  article-title: Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: Randomized controlled trial (PioRAGE)
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2014.03.025
– volume: 2016
  start-page: 6248264
  year: 2016
  ident: ref_40
  article-title: Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect
  publication-title: Dis. Markers
  doi: 10.1155/2016/6248264
– volume: 5
  start-page: 253
  year: 2010
  ident: ref_1
  article-title: Mammalian sirtuins: Biological insights and disease relevance
  publication-title: Annu. Rev. Pathol.
  doi: 10.1146/annurev.pathol.4.110807.092250
– volume: 15
  start-page: 788
  year: 2017
  ident: ref_7
  article-title: Serum concentrations and gene expression of sirtuin 1 in healthy and slightly overweight subjects after caloric restriction or resveratrol supplementation: A randomized trial
  publication-title: Int. J. Cardiol.
  doi: 10.1016/j.ijcard.2016.10.058
– volume: 26
  start-page: 1215
  year: 2016
  ident: ref_6
  article-title: Circulating SIRT1 Increases After Intragastric Balloon Fat Loss in Obese Patients
  publication-title: Obes. Surg.
  doi: 10.1007/s11695-015-1859-4
– volume: 310
  start-page: 314
  year: 2005
  ident: ref_3
  article-title: Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS
  publication-title: Science
  doi: 10.1126/science.1117728
– volume: 16
  start-page: 486
  year: 2001
  ident: ref_22
  article-title: RAGE and cardiovascular disease
  publication-title: Front. Biosci.
– volume: 13
  start-page: e23542
  year: 2015
  ident: ref_31
  article-title: Resveratrol-dependent down-regulation of receptor for advanced glycation end-products and oxidative stress in kidney of rats with diabetes
  publication-title: Int. J. Endocrinol. Metab.
  doi: 10.5812/ijem.23542
– volume: 425
  start-page: 191
  year: 2003
  ident: ref_20
  article-title: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
  publication-title: Nature
  doi: 10.1038/nature01960
– volume: 3
  start-page: 1
  year: 2012
  ident: ref_32
  article-title: Evolution of SR protein and hnRNP splicing regulatory factors
  publication-title: Wiley Interdiscip. Rev. RNA
  doi: 10.1002/wrna.100
– volume: 1290
  start-page: 122
  year: 2013
  ident: ref_21
  article-title: An adipocentric perspective of resveratrol as a calorie restriction mimetic
  publication-title: Ann. N. Y. Acad. Sci.
  doi: 10.1111/nyas.12212
– volume: 306
  start-page: 2105
  year: 2004
  ident: ref_4
  article-title: Nutrient availability regulates SIRT1 through a fork head dependent pathway
  publication-title: Science
  doi: 10.1126/science.1101731
– volume: 110
  start-page: 911
  year: 2010
  ident: ref_12
  article-title: Advanced glycation end products in foods and a practical guide to their reduction in the diet
  publication-title: J. Am. Diet. Assoc.
  doi: 10.1016/j.jada.2010.03.018
– volume: 81
  start-page: 1481
  year: 2010
  ident: ref_30
  article-title: Gingival RAGE expression in calorie-restricted versus ad libitum-fed rats
  publication-title: J. Periodontol.
  doi: 10.1902/jop.2010.100019
– ident: ref_36
  doi: 10.1371/journal.pone.0028926
– volume: 48
  start-page: 1018
  year: 2013
  ident: ref_19
  article-title: Resveratrol vs. calorie restriction: Data from rodents to humans
  publication-title: Exp. Gerontol.
  doi: 10.1016/j.exger.2013.04.005
– volume: 94
  start-page: 55
  year: 2013
  ident: ref_27
  article-title: RAGE regulation and signaling in inflammation and beyond
  publication-title: J. Leukoc. Biol.
  doi: 10.1189/jlb.1012519
– volume: 54
  start-page: 3052
  year: 2013
  ident: ref_38
  article-title: Statins stimulate the production of a soluble form of the receptor for advanced glycation end products
  publication-title: J. Lipid Res.
  doi: 10.1194/jlr.M038968
– volume: 127
  start-page: 1109
  year: 2006
  ident: ref_5
  article-title: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α
  publication-title: Cell
  doi: 10.1016/j.cell.2006.11.013
– volume: 22
  start-page: 1572
  year: 2008
  ident: ref_15
  article-title: Identification, classification, and expression of RAGE gene splice variants
  publication-title: FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.
– volume: 102
  start-page: 3756
  year: 2017
  ident: ref_29
  article-title: HbA1c Identifies Subjects with Prediabetes and Subclinical Left Ventricular Diastolic Dysfunction
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/jc.2017-00954
– volume: 101
  start-page: 1701
  year: 2016
  ident: ref_28
  article-title: Low endogenous secretory receptor for advanced glycation end-products levels are associated with inflammation and carotid atherosclerosis in prediabetes
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/jc.2015-4069
– volume: 143
  start-page: 1699
  year: 1993
  ident: ref_10
  article-title: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues
  publication-title: Am. J. Pathol.
– volume: 84
  start-page: 489
  year: 1999
  ident: ref_13
  article-title: Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
  publication-title: Circ. Res.
  doi: 10.1161/01.RES.84.5.489
– volume: 196
  start-page: 9
  year: 2008
  ident: ref_23
  article-title: Receptor of advanced glycation end products and atherosclerosis: From basis mechanisms to clinal implications
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2007.07.025
– volume: 59
  start-page: 1006
  year: 2010
  ident: ref_14
  article-title: Downregulation of the longevity-associated protein SIRT1 in insulin resistance and metabolic syndrome. Potential biochemical mechanisms
  publication-title: Diabetes
  doi: 10.2337/db09-1187
– volume: 62
  start-page: 2116
  year: 2013
  ident: ref_17
  article-title: sRAGE and risk of diabetes, cardiovascular disease, and death
  publication-title: Diabetes
  doi: 10.2337/db12-1528
– volume: 10
  start-page: 8931
  year: 2015
  ident: ref_18
  article-title: The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes
  publication-title: Sci. Rep.
  doi: 10.1038/srep08931
– volume: 83
  start-page: 876
  year: 2005
  ident: ref_25
  article-title: Understanding RAGE, the receptor for advanced glycation end products
  publication-title: J. Mol. Med.
  doi: 10.1007/s00109-005-0688-7
– volume: 133
  start-page: 187
  year: 2015
  ident: ref_33
  article-title: Regulation of RAGE splicing by hnRNP A1 and Tra2β-1 and its potential role in AD pathogenesis
  publication-title: J. Neurochem.
  doi: 10.1111/jnc.13069
– volume: 43
  start-page: 571
  year: 2007
  ident: ref_9
  article-title: Sirt1 modulates premature senescence-like phenotype in human endothelial cells
  publication-title: J. Mol. Cell. Cardiol.
  doi: 10.1016/j.yjmcc.2007.08.008
– reference: 26840489 - Nature. 2016 Feb 11;530(7589):184-9
– reference: 26337692 - Obes Surg. 2016 Jun;26(6):1215-20
– reference: 25754382 - Sci Rep. 2015 Mar 10;5:8931
– reference: 16133426 - J Mol Med (Berl). 2005 Nov;83(11):876-86
– reference: 28029409 - Int J Cardiol. 2017 Jan 15;227:788-794
– reference: 20572766 - J Periodontol. 2010 Oct;81(10):1481-7
– reference: 12429856 - Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15596-601
– reference: 8256857 - Am J Pathol. 1993 Dec;143(6):1699-712
– reference: 25689357 - J Neurochem. 2015 Apr;133(2):187-98
– reference: 12495433 - Biochem J. 2003 Mar 15;370(Pt 3):1097-109
– reference: 28515150 - FASEB J. 2017 Sep;31(9):3894-3903
– reference: 21898828 - Wiley Interdiscip Rev RNA. 2012 Jan-Feb;3(1):1-12
– reference: 20078221 - Annu Rev Pathol. 2010;5:253-95
– reference: 25892997 - Int J Endocrinol Metab. 2015 Apr 20;13(2):e23542
– reference: 18089847 - FASEB J. 2008 May;22(5):1572-80
– reference: 23966666 - J Lipid Res. 2013 Nov;54(11):3052-61
– reference: 27829696 - Dis Markers. 2016;2016:6248264
– reference: 23396398 - Diabetes. 2013 Jun;62(6):2116-21
– reference: 22174926 - PLoS One. 2011;6(12):e28926
– reference: 17916362 - J Mol Cell Cardiol. 2007 Nov;43(5):571-9
– reference: 23800577 - Biochim Biophys Acta. 2013 Oct;1830(10):4820-7
– reference: 12939617 - Nature. 2003 Sep 11;425(6954):191-6
– reference: 26885882 - J Clin Endocrinol Metab. 2016 Apr;101(4):1701-9
– reference: 17826783 - Atherosclerosis. 2008 Jan;196(1):9-21
– reference: 17112576 - Cell. 2006 Dec 15;127(6):1109-22
– reference: 20570900 - Cancer Res. 2010 Jul 1;70(13):5628-38
– reference: 20068143 - Diabetes. 2010 Apr;59(4):1006-15
– reference: 28973588 - J Clin Endocrinol Metab. 2017 Oct 1;102(10):3756-3764
– reference: 15987483 - Arthritis Res Ther. 2005;7(4):R817-24
– reference: 21196183 - Front Biosci (Landmark Ed). 2011 Jan 01;16:486-97
– reference: 15731496 - Arterioscler Thromb Vasc Biol. 2005 May;25(5):1032-7
– reference: 23855474 - Ann N Y Acad Sci. 2013 Jul;1290:122-9
– reference: 23624181 - Exp Gerontol. 2013 Oct;48(10):1018-24
– reference: 23543766 - J Leukoc Biol. 2013 Jul;94(1):55-68
– reference: 20350594 - Exp Gerontol. 2010 Jun;45(6):410-8
– reference: 15604409 - Science. 2004 Dec 17;306(5704):2105-8
– reference: 20497781 - J Am Diet Assoc. 2010 Jun;110(6):911-16.e12
– reference: 10082470 - Circ Res. 1999 Mar 19;84(5):489-97
– reference: 16224023 - Science. 2005 Oct 14;310(5746):314-7
– reference: 23747814 - Mech Ageing Dev. 2013 Sep;134(9):356-66
– reference: 24727234 - Atherosclerosis. 2014 Jun;234(2):329-34
SSID ssj0000070763
Score 2.2942064
Snippet Sirtuin-1 (Sirt-1) and an endogenous secretory receptor for an advanced glycation end product (esRAGE) are associated with vascular protection. The purpose of...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 937
SubjectTerms advanced glycation end products
Aged
blood serum
Caloric Restriction
Female
Gene expression
Gene Expression Regulation - drug effects
high density lipoprotein
Humans
low calorie diet
Male
Middle Aged
Overweight
Receptor for Advanced Glycation End Products - genetics
Receptor for Advanced Glycation End Products - metabolism
resveratrol
Sirtuin 1 - genetics
Sirtuin 1 - metabolism
Stilbenes - administration & dosage
Stilbenes - pharmacology
waist circumference
SummonAdditionalLinks – databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Jb9QwFLZKuXBBQFmGFvQQCIlDIGM7cXJAaFRNqZBYpGGk3iLHixgpeNpZUPML-Vu852QGplQ9REpkO9vz8n328_cYe5XXrhB17hNjtUikz2RSSGmTslRW1QhAShvVPr_kp1P56Sw722Ob-J39D1xeS-0ontR00by9vGg_YIN_T4wTKfu7sKalfqTm6ha7jSOSohAOn3uY38FghXRddOqkV4rsjkf_gcyrvpL_DD4n99jdHjXCqDPzfbbnwgN2MArImH-28BqiH2ecID9gv0lJGsaXvYdrgLmHyWyxWs9CMgQdLIyDnXfarDAh1Ejr7ID40Z3jGSCKhVHvGQAfm7ab06NC8K2Th13CLEC3f6mNN5w0RPGbFr5GN2u6AOyRaIpnCTEKORxrcvUz-BgKFBI3U8SieP2LdJ0Xc_y8HSHfh2x6Mv5-fJr04RoSg6hmlUhtPXYJNk1daoha8szUaHIEeCYnJpoaQp9a-dpmLsOjUNIrzbWXUphcPGL7YR7cEwaIyVTpvCkyn0cJNqe58JYLIYZ4agfszcZolem1zCmkRlMhpyEDV38NPGAvt3nPOwWPa3MdbWxfbSphxWlrBhK6YTlgL7bJ2P5oUUUHh3aqOGKuTCpe5Dfk4YgAUuw68T6Pu-q0fRVBCkBpXgyY2qlo2wyk_72bEmY_og54jt2zkuXTm1_9kN1BkFfQfDQfHrH91WLtniGQWtXPYyv5A00XIzE
  priority: 102
  providerName: Scholars Portal
Title Gene Expression of Sirtuin-1 and Endogenous Secretory Receptor for Advanced Glycation End Products in Healthy and Slightly Overweight Subjects after Caloric Restriction and Resveratrol Administration
URI https://www.ncbi.nlm.nih.gov/pubmed/30037068
https://www.proquest.com/docview/2108587519
https://www.proquest.com/docview/2075547286
https://www.proquest.com/docview/2271803229
https://pubmed.ncbi.nlm.nih.gov/PMC6073749
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEF5Be-GCgPIIlGoQCImDVdu73rVPKFRpKyRKRaiUm2XvQ40U1iEPRH4hf4uZteMSQD0k8sprx9Hszn4z-_kbxt7I2ua8li7SpuKRcJmIciFMVBTKqBoBSGGC2ueFPL8SHyfZpEu4LTta5dYnBkdtGk058uOUaPIIrpPi_fx7RFWjaHe1K6Fxl-2TdBkFX2qi-hxL0LKRvFUl5RjdH_s1sQIwile769A_4PJvjuQfi87pA3a_Q4swbM37kN2x_hE7GHqMlL9t4C0E_mZIjB-wX6QgDaOfHbPVQ-NgPF2s1lMfJVB5AyNvmlaTFcaEFml_HRA32jkeAaJXGHaMADibbdpcHl0El60s7BKmHtr3ljbhhuMZhfazDXwO9GpqAHoiSu0sIVQfh5OKKH4af4YKhISXKMKl2P5Bes6LBv_ejoDvY3Z1Ovp6ch51ZRoijWhmFYnKOHQFJo5trCmkTDNdo6kR2GlJEWisCXVWytUmsxl-ciWcqtLKCcG15E_Ynm-8fcYAsZgqrNN55mSQXrNVyp1JOecJHpoBe7c1Wqk7DXMqpTErMZYhA5c3Bh6w133feavc8d9eh1vbl93sXZY3Y23AXvWncd7RZkrlLdqpTBFrZUKlubylT4orf4wuE-_ztB1O_aNwUv6JZT5gameg9R1I93v3jJ9eB_1viW5ZieL57Y_-gt1DcJdTHjpNDtnearG2LxFAreqjMEuO2P6H0cXlF2ydTRL8_iTy38CvJMU
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELZKeoALAsojUGAQD4nDqhvb-zogFEpKSkuoSCv1tuzaXhEpOCEPIH-Kv8HfYsb7aAOotx4i7Wq9XkczHn8zHn_D2LMwN7HIw8JTOhOeLALpxVJqL0kiHeUIQBLt2D4HYf9Evj8NTjfYr_osDKVV1jbRGWo9URQj3-GUJo_gupO8nn7zqGoU7a7WJTRKtTgwqx_oss1f7b9F-T7nfK93vNv3qqoCnsLFd-HJTBeoudr3ja_IA-KBynFkiENUSA6TrwgkZVGR68AE-IsjWUQZzwophQoF9nuFbUqBUKHFNt_0BkefmqiOY88JRcmDKkTi79gl5SH4CRVaP7_y_QNn_87KPLfM7d1g1yt8Ct1SoW6yDWNvsa2uRd_86wpegMsYdaH4LfabOKuh97PKpbUwKWA4mi2WI-t1ILMaelZPShZYGBI-pR19QKRqpngFiJehW-UgwLvxqowe0ktwVBLRzmFkoTwptXIdDscUTBiv4KNL6KYbQNtHwaQ5uHrnsJtRUqHCz1BJEndsw72K99-JQXo2wb-3Rhl8m51cigjvsJadWHOPAaK_KDGFioMidGRvJuOi0FwI0cFL3WYva6GlqmJNp-Id4xS9JxJweibgNnvatJ2WXCH_bbVdyz6t7MU8PdPuNnvSPMaZTts3mTUop5QjugtkxOPwgjYcsYaPRhr7uVuqUzMUQVxDfhi3WbSmaE0DYhpff2JHXxzjeIgLQSST-xcP_TG72j_-cJge7g8OHrBrCC1jioLzzjZrLWZL8xDh2yJ_VM0ZYJ8ve5r-AV51Xtc
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIiEuCCiPQIFBPCQOVpxd22sfEIrahJaiUilUys219yEihU3IA_Bf4w_wt5hZO2kDqLceItnyer3RzM58Ozv7DWMvk9KkokxsoHQhgsjGUZBGkQ6yTGpZIgDJtGf7PE4OTqMPw3i4xX6tzsJQWuXKJnpDrSeKYuRtTmnyCK47Wds2aREn-_13028BVZCindZVOY1aRY5M9QOXb_O3h_so61ec93uf9w6CpsJAoNARL4Ko0Ba1WIehCRWthnisShwlYhKV0OIpVASYCmlLHZsYf6mMrCx4YaNIqERgv9fYdSnQbeJckkO5ju94Hp1E1IyoQmRh2y0pIyHMqOT6RR_4D7D9Oz_zgsPr32a3GqQK3Vq17rAt4-6yna7DVfrXCl6Dzx31Qfkd9pvYq6H3s8mqdTCxMBjNFsuRCzpQOA09pyc1HywMCKnS3j4gZjVTvAJEztBtshHg_biq44j0EpzUlLRzGDmoz0xVvsPBmMIK4wo--dRuugG0ghRWmoOvfA57BaUXKvwMFSfxBzj8q3j_nbikZxP8exvkwffY6ZUI8D7bdhNnHjJAHCgzY1Ua28TTvpmCC6u5EKKDl7rF3qyElquGP53KeIxzXEeRgPNzAbfYi3Xbac0a8t9WuyvZ543lmOfnet5iz9ePcc7TRk7hDMop54jz4kjyNLmkDUfUEaK5xn4e1Oq0Hoog1qEwSVtMbijaugFxjm8-caMvnns8QZcgo-zR5UN_xm7g5Mw_Hh4fPWY3EWOmFA7nnV22vZgtzRPEcYvyqZ8wwM6ueob-AXVFYac
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gene+Expression+of+Sirtuin-1+and+Endogenous+Secretory+Receptor+for+Advanced+Glycation+End+Products+in+Healthy+and+Slightly+Overweight+Subjects+after+Caloric+Restriction+and+Resveratrol+Administration&rft.jtitle=Nutrients&rft.au=Roggerio%2C+Alessandra&rft.au=C%C3%A9lia+M+Cassaro+Strunz&rft.au=Ana+Paula+Pacanaro&rft.au=Dalila+Pinheiro+Leal&rft.date=2018-07-21&rft.pub=MDPI+AG&rft.eissn=2072-6643&rft.volume=10&rft.issue=7&rft.spage=937&rft_id=info:doi/10.3390%2Fnu10070937&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6643&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6643&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6643&client=summon